(ORKA) Oruka Therapeutics - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6876041087
Monoclonal Antibody, Interleukin-23, Interleukin-17, Psoriasis, Clinical Trials
Description: ORKA Oruka Therapeutics October 21, 2025
Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biopharma based in Menlo Park, California, dedicated to creating monoclonal antibody treatments for psoriasis and broader inflammatory-immunology (I&I) diseases.
The lead assets are ORKA-001, a p19-IL-23 subunit inhibitor currently in a Phase 1 trial for plaque psoriasis, and ORKA-002, a dual IL-17A/IL-17F blocker being evaluated for psoriasis, psoriatic arthritis, and additional indications. The pipeline also includes ORKA-003 (targeting an undisclosed pathway) and ORKA-021, a sequential combination regimen of ORKA-002 followed by ORKA-001.
Key metrics as of the latest filing (Q2 2025): market capitalization ≈ $120 M, cash and equivalents of $45 M giving a runway of roughly 12-18 months at current burn (~$3 M / quarter). R&D spend has risen 38 % YoY, reflecting accelerated Phase 1/2 activity. The biotech sector’s valuation is being driven by strong demand for novel I&I therapies and a 7 % CAGR in global psoriasis drug spend, which could expand the addressable market for Oruka’s antibodies.
For a deeper, data-driven assessment of ORKA’s risk-adjusted upside, you may find the analyst tools on ValueRay useful for modeling scenario-based valuations.
ORKA Stock Overview
| Market Cap in USD | 1,313m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1997-08-08 |
ORKA Stock Ratings
| Growth Rating | 19.7% |
| Fundamental | 32.0% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -19.9% |
| Analyst Rating | 4.88 of 5 |
ORKA Dividends
Currently no dividends paidORKA Growth Ratios
| Growth Correlation 3m | 91.4% |
| Growth Correlation 12m | 7.5% |
| Growth Correlation 5y | -33.8% |
| CAGR 5y | 25.62% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.33 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.89 |
| Sharpe Ratio 12m | 0.21 |
| Alpha | -36.91 |
| Beta | |
| Volatility | 67.27% |
| Current Volume | 447.5k |
| Average Volume 20d | 404.8k |
| Stop Loss | 24.3 (-7.2%) |
| Signal | -1.29 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA 8.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 (>3.0%) and CFO -97.7m > Net Income -100.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 27.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.2m) change vs 12m ago 191.1% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -197.3 (EBITDA TTM -99.4m / Interest Expense TTM 504.0k) >= 6 (WARN >= 3) |
Altman Z'' -8.58
| (A) 0.90 = (Total Current Assets 332.0m - Total Current Liabilities 12.1m) / Total Assets 357.4m |
| (B) -0.36 = Retained Earnings (Balance) -129.3m / Total Assets 357.4m |
| (C) -0.51 = EBIT TTM -99.5m / Avg Total Assets 195.6m |
| (D) -9.38 = Book Value of Equity -129.3m / Total Liabilities 13.8m |
| Total Rating: -8.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.99
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -9.93% = -4.96 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.63 = 2.20 |
| 6. ROIC - WACC (= -33.86)% = -12.50 |
| 7. RoE -27.91% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend 45.19% = 2.26 |
What is the price of ORKA shares?
As of November 04, 2025, the stock is trading at USD 26.19 with a total of 447,500 shares traded.
Over the past week, the price has changed by -5.45%, over one month by +32.34%, over three months by +83.15% and over the past year by -2.82%.
Over the past week, the price has changed by -5.45%, over one month by +32.34%, over three months by +83.15% and over the past year by -2.82%.
Is Oruka Therapeutics a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Oruka Therapeutics (NASDAQ:ORKA) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 31.99 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ORKA is around 24.15 USD . This means that ORKA is currently overvalued and has a potential downside of -7.79%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ORKA is around 24.15 USD . This means that ORKA is currently overvalued and has a potential downside of -7.79%.
Is ORKA a buy, sell or hold?
Oruka Therapeutics has received a consensus analysts rating of 4.88.
Therefore, it is recommended to buy ORKA.
- Strong Buy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ORKA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.2 | 65% |
| Analysts Target Price | 43.2 | 65% |
| ValueRay Target Price | 27.7 | 5.8% |
ORKA Fundamental Data Overview October 25, 2025
Market Cap USD = 1.31b (1.31b USD * 1.0 USD.USD)
Beta = None
Revenue TTM = 0.0 USD
EBIT TTM = -99.5m USD
EBITDA TTM = -99.4m USD
Long Term Debt = 2.33m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 660.0k USD (from shortTermDebt, last quarter)
Debt = 2.33m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.1m USD (from netDebt column, last quarter)
Enterprise Value = 986.6m USD (1.31b + Debt 2.33m - CCE 328.4m)
Interest Coverage Ratio = -197.3 (Ebit TTM -99.5m / Interest Expense TTM 504.0k)
FCF Yield = -9.93% (FCF TTM -97.9m / Enterprise Value 986.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 31.0k) / Revenue TTM)
Tobins Q-Ratio = 2.76 (Enterprise Value 986.6m / Total Assets 357.4m)
Interest Expense / Debt = 21.67% (Interest Expense 504.0k / Debt 2.33m)
Taxrate = 21.0% (US default 21%)
NOPAT = -78.6m (EBIT -99.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.42 (Total Current Assets 332.0m / Total Current Liabilities 12.1m)
Debt / Equity = 0.01 (Debt 2.33m / totalStockholderEquity, last quarter 343.6m)
Debt / EBITDA = 0.63 (negative EBITDA) (Net Debt -63.1m / EBITDA -99.4m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -63.1m / FCF TTM -97.9m)
Total Stockholder Equity = 358.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.97% (Net Income -100.0m / Total Assets 357.4m)
RoE = -27.91% (Net Income TTM -100.0m / Total Stockholder Equity 358.2m)
RoCE = -27.58% (EBIT -99.5m / Capital Employed (Equity 358.2m + L.T.Debt 2.33m))
RoIC = -22.11% (negative operating profit) (NOPAT -78.6m / Invested Capital 355.3m)
WACC = 11.75% (E(1.31b)/V(1.31b) * Re(11.74%) + D(2.33m)/V(1.31b) * Rd(21.67%) * (1-Tc(0.21)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 71.16%
Fair Price DCF = unknown (Cash Flow -97.9m)
EPS Correlation: 45.19 | EPS CAGR: 77.22% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Beta = None
Revenue TTM = 0.0 USD
EBIT TTM = -99.5m USD
EBITDA TTM = -99.4m USD
Long Term Debt = 2.33m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 660.0k USD (from shortTermDebt, last quarter)
Debt = 2.33m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.1m USD (from netDebt column, last quarter)
Enterprise Value = 986.6m USD (1.31b + Debt 2.33m - CCE 328.4m)
Interest Coverage Ratio = -197.3 (Ebit TTM -99.5m / Interest Expense TTM 504.0k)
FCF Yield = -9.93% (FCF TTM -97.9m / Enterprise Value 986.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 31.0k) / Revenue TTM)
Tobins Q-Ratio = 2.76 (Enterprise Value 986.6m / Total Assets 357.4m)
Interest Expense / Debt = 21.67% (Interest Expense 504.0k / Debt 2.33m)
Taxrate = 21.0% (US default 21%)
NOPAT = -78.6m (EBIT -99.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.42 (Total Current Assets 332.0m / Total Current Liabilities 12.1m)
Debt / Equity = 0.01 (Debt 2.33m / totalStockholderEquity, last quarter 343.6m)
Debt / EBITDA = 0.63 (negative EBITDA) (Net Debt -63.1m / EBITDA -99.4m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -63.1m / FCF TTM -97.9m)
Total Stockholder Equity = 358.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.97% (Net Income -100.0m / Total Assets 357.4m)
RoE = -27.91% (Net Income TTM -100.0m / Total Stockholder Equity 358.2m)
RoCE = -27.58% (EBIT -99.5m / Capital Employed (Equity 358.2m + L.T.Debt 2.33m))
RoIC = -22.11% (negative operating profit) (NOPAT -78.6m / Invested Capital 355.3m)
WACC = 11.75% (E(1.31b)/V(1.31b) * Re(11.74%) + D(2.33m)/V(1.31b) * Rd(21.67%) * (1-Tc(0.21)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 71.16%
Fair Price DCF = unknown (Cash Flow -97.9m)
EPS Correlation: 45.19 | EPS CAGR: 77.22% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for ORKA Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle